335 related articles for article (PubMed ID: 28846068)
1. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
[TBL] [Abstract][Full Text] [Related]
2. Desacetylvinblastine Monohydrazide Disrupts Tumor Vessels by Promoting VE-cadherin Internalization.
Lei X; Chen M; Huang M; Li X; Shi C; Zhang D; Luo L; Zhang Y; Ma N; Chen H; Liang H; Ye W; Zhang D
Theranostics; 2018; 8(2):384-398. PubMed ID: 29290815
[TBL] [Abstract][Full Text] [Related]
3. The FAP
Ye G; Huang M; Li Y; Ouyang J; Chen M; Wen Q; Li X; Zeng H; Long P; Fan Z; Yin J; Ye W; Zhang D
Acta Pharm Sin B; 2022 Mar; 12(3):1288-1304. PubMed ID: 35530139
[TBL] [Abstract][Full Text] [Related]
4. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
Foley KP; Zhou D; Borella C; Wu Y; Zhang M; Jiang J; Li H; Sang J; Korbut T; Ye J; Zhang X; Barsoum J; Sonderfan AJ
J Pharmacol Exp Ther; 2012 Nov; 343(2):529-38. PubMed ID: 22837008
[TBL] [Abstract][Full Text] [Related]
5. A vascular disrupting agent overcomes tumor multidrug resistance by skewing macrophage polarity toward the M1 phenotype.
Lei X; Chen M; Li X; Huang M; Nie Q; Ma N; Chen H; Xu N; Ye W; Zhang D
Cancer Lett; 2018 Apr; 418():239-249. PubMed ID: 29337108
[TBL] [Abstract][Full Text] [Related]
6. A novel FAPα-based Z-Gly-Pro epirubicin prodrug for improving tumor-targeting chemotherapy.
Wang J; Li Q; Li X; Yuan W; Huang S; Cai S; Xu J
Eur J Pharmacol; 2017 Nov; 815():166-172. PubMed ID: 28919026
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy.
Wu XY; Ma W; Gurung K; Guo CH
J Formos Med Assoc; 2013 Mar; 112(3):115-24. PubMed ID: 23473523
[TBL] [Abstract][Full Text] [Related]
8. Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions.
Liang W; Ni Y; Chen F
Oncotarget; 2016 Mar; 7(13):15444-59. PubMed ID: 26812886
[TBL] [Abstract][Full Text] [Related]
9. Vascular disrupting agents: a new class of drug in cancer therapy.
Gaya AM; Rustin GJ
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
[TBL] [Abstract][Full Text] [Related]
10. A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy.
Crielaard BJ; van der Wal S; Lammers T; Le HT; Hennink WE; Schiffelers RM; Storm G; Fens MH
Int J Nanomedicine; 2011; 6():2697-703. PubMed ID: 22114500
[TBL] [Abstract][Full Text] [Related]
11. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.
Taylor M; Billiot F; Marty V; Rouffiac V; Cohen P; Tournay E; Opolon P; Louache F; Vassal G; Laplace-Builhé C; Vielh P; Soria JC; Farace F
Cancer Discov; 2012 May; 2(5):434-49. PubMed ID: 22588881
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anti-tumor efficiency of gemcitabine prodrug by FAPα-mediated activation.
Sun J; Yang D; Cui SH; Zhang HT; Fu Y; Wang JC; Zhang Q
Int J Pharm; 2019 Mar; 559():48-57. PubMed ID: 30677483
[TBL] [Abstract][Full Text] [Related]
13. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.
Canela MD; Noppen S; Bueno O; Prota AE; Bargsten K; Sáez-Calvo G; Jimeno ML; Benkheil M; Ribatti D; Velázquez S; Camarasa MJ; Díaz JF; Steinmetz MO; Priego EM; Pérez-Pérez MJ; Liekens S
Oncotarget; 2017 Feb; 8(9):14325-14342. PubMed ID: 27224920
[TBL] [Abstract][Full Text] [Related]
14. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
[TBL] [Abstract][Full Text] [Related]
15. Vascular disrupting agents.
Pilat MJ; Lorusso PM
J Cell Biochem; 2006 Nov; 99(4):1021-39. PubMed ID: 16927308
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
Close A
Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
[TBL] [Abstract][Full Text] [Related]
17. Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.
Seidi K; Jahanban-Esfahlan R; Zarghami N
Tumour Biol; 2017 Mar; 39(3):1010428317691001. PubMed ID: 28351332
[TBL] [Abstract][Full Text] [Related]
18. Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
Gevertz JL
Adv Exp Med Biol; 2016; 936():191-208. PubMed ID: 27739049
[TBL] [Abstract][Full Text] [Related]
19. Combination of vascular disrupting agents and ionizing radiation.
Clémenson C; Chargari C; Deutsch E
Crit Rev Oncol Hematol; 2013 May; 86(2):143-60. PubMed ID: 23177097
[TBL] [Abstract][Full Text] [Related]
20. Pericytes and vessel maturation during tumor angiogenesis and metastasis.
Raza A; Franklin MJ; Dudek AZ
Am J Hematol; 2010 Aug; 85(8):593-8. PubMed ID: 20540157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
